---
schema_version: "secwatch.filing_event.v1"
accession: "0001818331-25-000105"
form_type: "8-K"
ticker: "WGS"
cik: "0001818331"
company_name: "GeneDx Holdings Corp."
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:46:58.140967+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# GeneDx Q2 revenue $102.7M (+49% YoY); raises FY outlook to $400-415M

## Summary
- Exome/genome test revenue $85.9M (+69% YoY) on volume of 23,102 results (+28%).
- Adjusted net income $15.0M vs. loss of $2.0M a year ago; GAAP net income $10.8M.
- Adjusted gross margin expanded to 71% from 62% in Q2 2024.
- Acquired Fabric Genomics for $33.2M in cash, net of cash acquired.
- AAP now recommends exome/genome as first-line test for children with global developmental delay.

## SEC filing metadata
- accession: 0001818331-25-000105
- form_type: 8-K
- ticker: WGS
- cik: 0001818331
- company_name: GeneDx Holdings Corp.
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818331/000181833125000105/0001818331-25-000105-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818331/000181833125000105/wgs-20250729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818331-25-000105
- JSON: https://secwatch.observer/filing/0001818331-25-000105.json
- Plain text: https://secwatch.observer/filing/0001818331-25-000105.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.